Is metronomic cyclophosphamide (mCTX) a therapeutic option for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the era of new agents (NAs)? A retrospective multicenter Italian study.

被引：0
|
作者：
Caffo, Orazio
De Giorgi, Ugo
Ferra, Francesco
Donini, Maddalena
Facchini, Gaetano
Maruzzo, Marco
Tucci, Marcello
Conteduca, Vincenza
Maines, Francesca
Rossi, Lorena
Veccia, Antonello
Galligioni, Enzo
机构：
[1] Santa Chiara Hosp, Trento, Italy
[2] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Meldola, Italy
[3] Osped S Vincenzo, Dept Med Oncol, Taormina, Italy
[4] Ist Ospitalieri Cremona, Cremona, Italy
[5] Ist Nazl Tumori Fdn G Pascale IRCCS, Med Oncol 1Div, Dept Urogynaecol Oncol, Naples, Italy
[6] IRCCS, Dept Clin & Expt Oncol, Med Oncol 1, IOV, Padua, Italy
[7] AOU San Luigi Gonzaga, Dept Oncol, Orbassano, TO, Italy
[8] IRCCS Ist Sci Romagnolo Studio & Cura Tumori, Meldola, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 02期
关键词：
D O I：
10.1200/jco.2016.34.2_suppl.326
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
326
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Fea, E.
    Vanella, P.
    Miraglio, E.
    Cauchi, C.
    Colantonio, I.
    Denaro, N.
    Di Costanzo, G.
    Garrone, O.
    Granetto, C.
    Occelli, M.
    Ricci, V.
    Vandone, A. M.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] Impact of new agents (NAs) on survival of metastatic castration-resistant prostate cancer (mCRPC) patients (pts): A single-Institution retrospective analysis.
    Caffo, Orazio
    Kinspergher, Stefania
    Maines, Francesca
    Macrini, Sveva
    Veccia, Antonello
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [3] Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting: Final analysis from a multicenter Italian study.
    Caffo, Orazio
    Bria, Emilio
    De Giorgi, Ugo
    Tucci, Marcello
    Galli, Luca
    Fratino, Lucia
    Rossetti, Sabrina
    Iacovelli, Roberto
    Lo Re, Giovanni
    Mosillo, Claudia
    Gasparro, Donatello
    Guglielmini, Pamela Francesca
    Damiani, Azzurra
    Procopio, Giuseppe
    De Lisi, Delia
    Ruatta, Fiorella
    Scagliarini, Sarah
    Donini, Maddalena
    Sperduti, Isabella
    Basso, Umberto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).
    Veccia, Antonello
    Caffo, Orazio
    Burgio, Salvatore Luca
    di Lorenzo, Giuseppe
    Ortega, Cinzia
    Scognamiglio, Florinda
    Mattioli, Rodolfo
    Mansueto, Giovanni
    Zustovich, Fable
    Aieta, Michele
    Facchini, Gaetano
    Procopio, Giuseppe
    D'Angelo, Alessandro
    Spizzo, Gilbert
    De Giorgi, Ugo
    De Placido, Sabino
    Ruatta, Fiorella
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] New agents (nas) in metastatic castration-resistant prostate cancer (mcrpc): is there a sequence better than the others?
    Maines, F.
    Caffo, O.
    Veccia, A.
    Galligioni, E.
    Trentin, C.
    Tortora, G.
    Bria, E.
    ANNALS OF ONCOLOGY, 2015, 26 : 61 - 62
  • [6] Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer
    Caffo, Orazio
    Facchini, Gaetano
    Biasco, Elisa
    Ferrau, Francesco
    Morelli, Franco
    Donini, Maddalena
    Buttigliero, Consuelo
    Calvani, Nicola
    Guida, Annalisa
    Chiuri, Vincenzo Emanuele
    Basso, Umberto
    Mucciarini, Claudia
    Conteduca, Vincenza
    Rossetti, Sabrina
    Veccia, Antonello
    Maines, Francesca
    Kinspergher, Stefania
    De Giorgi, Ugo
    FUTURE ONCOLOGY, 2019, 15 (10) : 1115 - 1123
  • [7] Treatment sequence in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in a prospective cohort study.
    Jose Mendez-Vidal, Maria
    Lozano, Rebeca
    Castro, Elena
    Romero-Laorden, Nuria
    Rodriguez-Vida, Alejo
    Lainez, Nuria
    Hernandez, Amaia
    Villatoro, Rosa
    Zambrana, Francisco
    Villa Guzman, Jose Carlos
    Garcia Dominguez, Rocio
    Galvan Ruiz, Saray
    Escribano, Ricardo
    Gallardo Diaz, Enrique
    Querol, Rosa
    Luque, Raquel
    Gonzalez del Alba, Aranzazu
    Puente, Javier
    Olmos, David
    Lorente, David
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
    Caffo, O.
    Biasco, E.
    Facchini, G.
    Fratino, L.
    Gasparro, D.
    Mosillo, C.
    Basso, U.
    Santini, D.
    Tucci, M.
    Ortega, C.
    Verderame, F.
    Scagliarini, S.
    Lo Re, G.
    Procopio, G.
    Fornarini, G.
    Campadelli, E.
    Sabbatini, R.
    Maines, F.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2016, 27
  • [9] Metronomic chemotherapy with oral cyclophosphamide. An individual option for the metastatic castration-resistant prostate cancer patient?
    Knipper, S.
    Mandel, P.
    Amsberg, G. V.
    Stroelin, P.
    Graefen, M.
    Steuber, T.
    UROLOGE, 2019, 58 (04): : 410 - 417
  • [10] Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study
    Caffo, O.
    Biasco, E.
    Facchini, G.
    Fratino, L.
    Gasparro, D.
    Mosillo, C.
    Maruzzo, M.
    Santini, D.
    Tucci, M.
    Ortega, C.
    Verderame, F.
    Scagliarini, S.
    Lo Re, G.
    Procopio, G.
    Fornarini, G.
    Campadelli, E.
    Sabbatini, R.
    Maines, F.
    De Giorgi, U.
    ANNALS OF ONCOLOGY, 2016, 27
12345